438185
Lovastatin
Lovastatin, CAS 75330-75-5, is an anti-hypercholesterolemic agent that inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.
Synonym(s):
Lovastatin, Mevinolin, MK-803, L-Type Calcium Channel Blocker IV
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C24H36O5
CAS Number:
Molecular Weight:
404.54
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Recommended Products
Quality Level
Assay
≥95% (HPLC)
form
powder
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
color
white to off-white
solubility
ethanol: 25 mg/mL
DMSO: 50 mg/mL
shipped in
ambient
storage temp.
2-8°C
InChI
1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
InChI key
PCZOHLXUXFIOCF-BXMDZJJMSA-N
General description
An anti-hypercholesterolemic agent and an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase that blocks a series of biological events including: activation of p21ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes, farnesylation of p21ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin), and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G1 phase. Shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and block the transcription of the type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF. This product requires activation for use in cell synchronization studies and in cell-free assay systems for HMG-CoA studies.
An anti-hypercholesterolemic agent that inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Has been shown to block a series of biological events including: the activation of p21ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes; the farnesylation of p21ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin); and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G1 phase through inhibition of proteasome. Has recently been shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and to block the transcription of type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF. This product requires activation for use in cell synchronization studies and in cell-free assay systems for HMG-CoA studies.
Biochem/physiol Actions
Cell permeable: no
Primary Target
Activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
Activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
Product does not compete with ATP.
Reversible: no
Warning
Toxicity: Carcinogenic / Teratogenic (D)
Reconstitution
Following reconstitution aliquot, flush with an inert gas, and freeze (-20°C). Stock solutions, in high quality DMSO or ethanol are stable for up to 1 month at -20°C.
Other Notes
Rao, S., et al. 1999. Proc. Natl. Acad. Sci. USA96, 7197.
Carel, K., et al. 1996. J. Biol. Chem.271, 30625.
McGuire, T.F., et al. 1996. J. Biol. Chem. 271, 27402.
Umetani, N., et al. 1996. Biochim. Biophys. Acta1303, 199.
Xu, X.Q., et al. 1996. Arch. Biochem. Biophys. 326, 233.
Reusch, J.E.-B., et al. 1995. J. Biol. Chem.270, 2036.
Jakobisiak, M., et al. 1991. Proc. Natl. Acad.Sci. USA88, 3628.
Keyomarsi, K., et al. 1991. Cancer Res.51, 3602.
Mendola, C.E., and Backer, J.M. 1990. Cell Growth Differ. 1, 499.
Carel, K., et al. 1996. J. Biol. Chem.271, 30625.
McGuire, T.F., et al. 1996. J. Biol. Chem. 271, 27402.
Umetani, N., et al. 1996. Biochim. Biophys. Acta1303, 199.
Xu, X.Q., et al. 1996. Arch. Biochem. Biophys. 326, 233.
Reusch, J.E.-B., et al. 1995. J. Biol. Chem.270, 2036.
Jakobisiak, M., et al. 1991. Proc. Natl. Acad.Sci. USA88, 3628.
Keyomarsi, K., et al. 1991. Cancer Res.51, 3602.
Mendola, C.E., and Backer, J.M. 1990. Cell Growth Differ. 1, 499.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Carc. 2 - Repr. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Martha M Monick et al.
Journal of immunology (Baltimore, Md. : 1950), 171(5), 2625-2630 (2003-08-21)
These studies demonstrate that treatment of macrophages with lovastatin, a cholesterol-lowering drug that blocks farnesylation and geranylgeranylation of target proteins, increases LPS-induced TNF-alpha production. This is reversed by the addition of mevalonate, which bypasses the lovastatin block. Examination of membrane
Cep57 and Cep57L1 maintain centriole engagement in interphase to ensure centriole duplication cycle.
Kei K Ito et al.
The Journal of cell biology, 220(3) (2021-01-26)
Centrioles duplicate in interphase only once per cell cycle. Newly formed centrioles remain associated with their mother centrioles. The two centrioles disengage at the end of mitosis, which licenses centriole duplication in the next cell cycle. Therefore, timely centriole disengagement
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service